Compare EXYN & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXYN | CTXR |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 18.7M |
| IPO Year | 2026 | 2010 |
| Metric | EXYN | CTXR |
|---|---|---|
| Price | $2.34 | $0.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 77.4K | ★ 181.6K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $0.47 |
| 52 Week High | $6.98 | $2.19 |
| Indicator | EXYN | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 37.39 | 44.72 |
| Support Level | $1.58 | $0.55 |
| Resistance Level | $2.86 | $0.61 |
| Average True Range (ATR) | 0.21 | 0.03 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 9.09 | 35.87 |
Exyn Technologies Inc is a pioneer in fully adaptive, cognitive mission-level autonomous robotics and artificial intelligence, delivering solutions that enable safe, efficient, and scalable autonomy in complex, GPS-denied environments. Its mission is to deliver world-class autonomous robots to data-hungry industries, unlocking new insights that drive smarter decisions. The group is leveraging proprietary Level 4B autonomy software and cutting-edge aerial and ground robotic systems. It empowers industries, including mining, construction, critical infrastructure, and defense, with real-time 3D mapping, data analytics, and autonomous navigation. Its software and hardware include ExynAI, ExynAI SDK, ExynView, Nexys, Accessories, and Platforms.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.